4.0 Article

Monobactam Treatment of multidrug-resistant Enterobacteriaceae infections

Journal

DRUGS OF THE FUTURE
Volume 48, Issue 2, Pages 81-91

Publisher

PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dof.2023.48.2.3400571

Keywords

Ancremonam; LYS-228; BOS-228; Enterobac-teriaceae; Multidrug-resistant infections

Ask authors/readers for more resources

Ancremonam, developed by Novartis, is an experimental mono-bactam that can effectively combat a wide range of ESBL-producing Enterobacteriaceae, including metallo-13-lactamases (MBLs). It has demonstrated efficacy in various infection models and has shown good safety and tolerability in a phase I clinical trial. Currently, Ancremonam is in phase II clinical development by Boston Pharmaceuticals.
Ancremonam (LYS-228, BOS-228) is an experimental mono-bactam developed by Novartis, which is active against a wide range of extended-spectrum 13-lactamase (ESBL)-producing Enterobacteriaceae including metallo-13-lactamases (MBLs), like New Delhi metallo-13-lactamase (NDM-1), and serine-13- lactamases (SBLs) expressing clinical strains. Its in vivo efficacy has been demonstrated against various strains of Escherich-ia coli and Klebsiella pneumoniae harboring different ESBL-, MBL-and SBL-producing genes in immuno-competent and neutropenic murine thigh infection models, as well as an as-cending pyelonephritis model. Ancremonam was found to be safe and tolerable with statistically insignificant mild adverse events among ancremonam-and placebo-treated cohorts in a phase I clinical trial conducted in healthy volunteers. An-cremonam is under phase II clinical development by Boston Pharmaceuticals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available